Innoviva Inc

NASDAQ:INVA

18.77

-0.29 (-1.52%)

7:44:35 PM EDT: $17.86 -0.91 (-4.85%)

Market Cap (Intraday)	1.16B
Current PE	N/A
Forward PE	24.7
2yr Forward PE	8.31

See more stats

Estimates Current Quarter

Revenue	$87.13 Million
Adjusted EPS	$0.43

See more estimates

10-Day MA	$19.38
50-Day MA	$19.72
200-Day MA	$18.83

See more pivots

Innoviva Inc Stock, NASDAQ:INVA

1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010

United States of America

Phone: +1.650.238.9600

Number of Employees: 127

http://www.inva.com

Description

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.